Hematologic Oncology Update Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part Series
Oct 20, 2023
Dr Naval Daver from The University of Texas MD Anderson Cancer Center discusses optimizing the management of acute myeloid leukemia and myelodysplastic syndromes. Topics include the productivity of researchers in leukemia, the potential of checkpoint inhibitors, challenges of managing TP53 mutated disease, various drug therapies for AML and MDS, management of qtc prolongation, combination therapy, and the continuation of Van Aza treatment.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8
Introduction
00:00 • 4min
Productivity in Research and Classification of Acute Myeloid Leukemia and Myelodysplastic Syndromes
03:37 • 4min
The Potential of Checkpoint Inhibitors in AML and MDS
07:18 • 2min
Challenges of managing TP 53 mutated disease with complex cytogenetics in AML
09:10 • 7min
Various Drug Therapies for AML and MDS
16:31 • 14min
Management of qtc Prolongation in Patients with Mutations and Evaluation of Iveocidinib
30:16 • 4min
Combination Therapy in AML and MDS
34:03 • 26min
Discussion on the Management of AML and the Continuation of Van Aza
01:00:00 • 2min